孙璐, 刘翔宇, 于虎, 王珂, 刘文欣. 甲磺酸阿帕替尼治疗二线化疗失败上皮性卵巢癌的疗效分析[J]. 中国肿瘤临床, 2019, 46(12): 627-630. DOI: 10.3969/j.issn.1000-8179.2019.12.159
引用本文: 孙璐, 刘翔宇, 于虎, 王珂, 刘文欣. 甲磺酸阿帕替尼治疗二线化疗失败上皮性卵巢癌的疗效分析[J]. 中国肿瘤临床, 2019, 46(12): 627-630. DOI: 10.3969/j.issn.1000-8179.2019.12.159
shu
Sun Lu, Liu Xiangyu, Yu Hu, Wang Ke, Liu Wenxin. Evaluation of efficacy and safety of apatinib for patients with recurrent epithelial ovarian cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 46(12): 627-630. DOI: 10.3969/j.issn.1000-8179.2019.12.159
Citation: Sun Lu, Liu Xiangyu, Yu Hu, Wang Ke, Liu Wenxin. Evaluation of efficacy and safety of apatinib for patients with recurrent epithelial ovarian cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 46(12): 627-630. DOI: 10.3969/j.issn.1000-8179.2019.12.159
shu

甲磺酸阿帕替尼治疗二线化疗失败上皮性卵巢癌的疗效分析

Evaluation of efficacy and safety of apatinib for patients with recurrent epithelial ovarian cancer

    摘要
  • 摘要:
      目的  探讨甲磺酸阿帕替尼治疗二线化疗失败上皮性卵巢癌（epithelial ovarian cancer，EOC）患者的疗效与安全性。
      方法  收集2017年9月至2018年11月46例天津医科大学肿瘤医院收治的二线化疗失败的复发性EOC患者的临床资料，分析甲磺酸阿帕替尼的疗效及治疗相关的不良事件，并评估其安全性。
      结果  46例患者的中位随访时间为12个月，中位总生存（overall survival，OS）时间为6（2~15）个月。客观缓解率（objective response rate，ORR）为26.1%（12/46），疾病控制率（disease control rate，DCR）为86.9%（40/46）。46例患者中30例（65.2%）出现不良反应，主要为1~2级，最常见的治疗相关不良反应为高血压占39.1%（18/ 46），手足皮肤综合征占30.4%（14/46），仅1例患者出现3级治疗相关性高血压，所有患者的1、2级不良事件均能迅速缓解，且甲磺酸阿帕替尼治疗后患者耐受性良好。
      结论  甲磺酸阿帕替尼对于二线化疗失败的EOC患者可能是一种安全且有效的治疗选择，但仍需开展大规模的临床试验进一步研究。

     

    Abstract:
      Objective  To assess the efficacy and safety of apatinib for patients with epithelial ovarian cancer (EOC) who had failed in second-line chemotherapy.
      Methods  The clinical data of 46 patients with recurrent EOC who had failed in second-line chemotherapy and were admitted to the Cancer Hospital of Tianjin Medical University from September 2017 to November 2018 were collected. The treatment efficacy of apatinib was evaluated, and treatment-related adverse events (AEs) were recorded to evaluate its safety.
      Results  A total of 46 eligible patients were enrolled. The median follow- up time was 12 months. The median overall survival (OS) was 6 months (range 2-15 months). The objective response rate (ORR) was 26.1% (12/46 patients), and the disease control rate (DCR) was 86.9% (40/46 patients). AEs occurred in 30 patients (65.2%), and were mainly of grade 1-2. The most common treatment-related AEs were hypertension (39.1%) and hand-foot-skin syndrome (30.4%); only one patient experienced grade 3 treatment-related hypertension. All grade 1-2 AEs could be recovered rapidly and well-tolerated after treatment with medication.
      Conclusions  Apatinib may be a safe and effective option for patients with advanced EOC who had failed in second-line chemotherapy. Further Studies are warranted in large-scale clinical trials.

     

    • HTML全文
    • 参考文献(15)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回